Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 377 across all filing types
Latest filing 2023-04-19 Major Shareholding Noti…
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for an individual ('Ranny Davidoff') in the issuer ('Immunovia AB (publ)'). It explicitly shows the 'Before the transaction' and 'After the transaction' share counts, voting rights, and the resulting percentage, noting the 'Reason for major shareholding notification Sell'. This structure is characteristic of a notification regarding a change in significant ownership, which aligns with the definition for Major Shareholding Notification (MRQ). The document is short and appears to be the official filing itself, not an announcement of a filing.
2023-04-19 English
Immunovia announces outcome of the rights issue
Capital/Financing Update Classification · 98% confidence The document is explicitly titled "PRESS RELEASE" and announces the "outcome of the rights issue." A rights issue is a method of raising capital by offering new shares to existing shareholders. This directly relates to fundraising and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not a full 10-K, an Earnings Release (ER), or a simple Dividend Notice (DIV). It is a specific announcement about a capital raising event.
2023-04-12 English
Immunovia offentliggör utfall i företrädesemissionen
Capital/Financing Update Classification · 98% confidence The document is titled "Immunovia offentliggör utfall i företrädesemissionen" (Immunovia announces outcome of the rights issue) and details the subscription rates, the total amount raised (approx. 151.8 MSEK), changes in share capital and the total number of shares following the rights issue. This clearly relates to a corporate financing activity, specifically the completion and results of a capital raise (rights issue). This aligns directly with the definition for Capital/Financing Update (CAP). Although it mentions a Prospekt (Prospectus) was published earlier, this document is the announcement of the *outcome* of that financing event, not the announcement of the report itself (RPA) or the prospectus itself.
2023-04-12 Swedish
Immunovia offentliggör prospekt i samband med företrädesemissionen
Report Publication Announcement Classification · 99% confidence The document is a press release titled "Immunovia offentliggör prospekt i samband med företrädesemissionen" (Immunovia publishes prospectus in connection with the rights issue). It explicitly states that the prospectus regarding the rights issue has been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen) and is now available on the company's website. It also details the timeline for the rights issue (subscription period, trading of warrants, etc.). This document is not the full prospectus itself, but an announcement that the prospectus has been published and is available. According to Rule 2, when a document announces the publication of a report (like a prospectus) and provides details about the event (rights issue), it fits the description of a Report Publication Announcement (RPA). It is not a general regulatory filing (RNS) because it is specific to the publication of a key document (the prospectus) related to a financing event.
2023-03-17 Swedish
Immunovia publishes prospectus relating to the rights issue
Capital/Financing Update Classification · 95% confidence The document is explicitly titled "Immunovia publishes prospectus relating to the rights issue" and states that the prospectus has been approved and registered by the Financial Supervisory Authority and is now available. This document itself is a press release announcing the availability of a formal offering document (the prospectus) related to a capital raising activity (Rights Issue). Since the document is an announcement about the publication of a formal document, and it details the timetable for the capital raise, it strongly aligns with the definition of a Capital/Financing Update (CAP). While it announces a prospectus, the core subject is the financing event itself. If the document were the prospectus itself, it would be classified differently, but as a press release announcing its availability and detailing the timeline, CAP is the most appropriate fit among the provided options, as it concerns fundraising/capital structure changes. It is not a general regulatory filing (RNS) because it is highly specific to financing.
2023-03-17 English
Bulletin from the extraordinary general meeting in Immunovia AB
Capital/Financing Update Classification · 95% confidence The document is titled 'Bulletin from the extraordinary general meeting in Immunovia AB' and details resolutions passed at an EGM, specifically concerning the approval of a rights issue to increase share capital. This action—a significant change in capital structure approved by shareholders—falls under the scope of financing activities and capital structure changes. The most appropriate category is 'Capital/Financing Update' (CAP). While it relates to an EGM, the core subject is the capital increase, not the general meeting proceedings or voting results themselves, making CAP more specific than AGM-R or DVA.
2023-03-16 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.